DETECTION OF DNA DAMAGE

Abstract: The health condition of a living organism is detected by electrochemically analyzing samples from selected areas of the body of said living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage.

Description: 1 DETECTION OF DNA DAMAGE 2 Field of the Invention 3 The present invention relates to improvements in diagnostic 4 techniques, and more particularly to diagnostic techniques for detecting and 5 identifying DNA or RNA damage. The invention has particular utility in the 6 detection of cervical cancer and will be described in connection with such 7 utility, although other utilities are contemplated, as will be discussed below in 8 detail, including detection of other cancers and other disease conditions, as 9 well as health conditions brought out by exposure to environmental insults I ϋ such as radiation, metals, smoke and solvents. II Background of the Invention 12 The current gold standard for detecting cervical cancer in women is the 13 so-called "PAP Smear." However, the reliability of PAP Smear testing, which 14 relies upon a technician's observations, under the microscope, of cellular 15 morphology, may be compromised by technician fatigue and/ or subjectivity. ' 16 Even very experienced technicians may misread a slide. If a false-positive is 17 "called" or the slide results in an "uncertain" call, the physical may err on the 18 side of the patient's safetv, and call for a hysterectomy (uterus removal) or 19 total hysterectomy (uterus and ovary removal). This results in the patient 20 taking a lifetime dose of hormone replacement medications to keep the body 21 in balance. Of course, the failure to identify "a pre-cancerous condition" 22 could lead to an even more disastrous result to a patient. 23 Object of the Invention 24 It is thus a primary object of the invention to overcome the aforesaid 25 and other disadvantages of the prior art. Another object of the invention is to 26 provide an analytical technique for detecting and diagnosing disease 27 conditions, as well as health conditions due to exposure to environmental 28 conditions, by detecting and identifying DNA or RNA damage markers. 29 Another more object of the invention is to provide a reliable, totally objective 30 analytical technique for detecting cancer. Brief Description of the Invention In order to effect the foregoing and other objects, the present invention provides an analytical technique for detecting cancer or other disease and/or health conditions based on measurement of free levels of nucleotide excision products resulting from DNA or RNA damage, such as 80H2'dG-8 hydroxy 2' deoxyguanosine; 06MG - O-6-methylguanine; 2'dG - 2'deoxyguanosine; 7MG - 7-methylguanine; 8NG - 8-nitroguanine; 80HG - 8-hydroxyguanine; 80H2'dA - 8-hydroxy-2-deoxyadenosine; 80HA - 8-hydroxyadenine; 50H2'dCy - 5-hydroxy 2'deoxycytidine; 50HU - 5 - hydroxyuracil; 3NT - 3- nitrotyrosine; or 3 C1T - 3-chlorotyrosine in biological samples from selected areas of the body. More particularly, the present invention is based on the hypothesis that specific areas of the body are semi-isolated in-situ biochemical environments for nucleotide excision products such as 80H2'dG or other nucleotide excision products, and that the levels of such free 80H2'dG or other nucleotide excision products in the semi-isolated environment magnify the combined defects of DNA or RNA damage and repair mechanisms. By way of specific example, the effective damage and repair rate increases in DNA in cancer, or pre-cancerous cells, has been found to be magnified bv accumulation in the extra-cellular matrix in selected areas of the body of 80H2'dG. For example, as applied to cervical cancer, the cervix has been found to be a semi-isolated in-situ biochemical environment which may be accessed through cervico vaginal lavage sampling. Thus, an objective analytical technique for determination of cervical cancer is provided. Brief Description of the Drawings For a further understand of nature and objects of the present invention, presence should be had to the following detailed description taken in conjunction with the accompanying drawings wherein: 1 Fig. 1 is a schematic view of one form of sample separation and 2 analysis system in accordance with the preferred embodiment of the 3 invention; 4 Fig. 2 is a side elevational view, in cross section, showing details of a 5 preferred form of sample preparation column useful in accordance with a 6 preferred embodiment of the present invention; 7 Pig. 3 is a side elevational view, in cross section, of a separation and/ or 8 testing column controlled as an electrochemical cell useful in accordance with 9 a preferred embodiment of the invention; 10 Figs. 4 and 5 are a series of graphs showing the current over time of an 11 electrochemical analysis for 80H2'dG and 06MG, respectively, in cervico 1.2 vaginal lavage samples in accordance with the present invention; and 13 Fig. 6 are coulometric electrode array system patterns of PAP smear 14 samples in accordance with the present invention. 15 Detailed Description of the Preferred Embodiment of the Invention 1.6 Further understanding of the features and advantages of the present 17 invention will be had from the following detailed description of the invention, 18 which illustrates the electrochemical analysis of 8 hydroxy 2 1 deoxyguanosine 19 (80H2'dG) in cervico vaginal lavage or PAP smear swab samples. Analysis 20 is accomplished using an electrochemical analytical system made in 21 accordance with and following the general analytical procedures disclosed in 22 PCT Application No. PCT/ US98/ 22275, and as discussed in "A Carbon 23 Column Based LCEC Approach to Routine 8-Hydroxy-2'-Doxyguanosine 24 Measurements in Urine and Other Biological Matrices" (Bogdanov MB, et a. 25 Free Rad. Ciol. Med. 27, 1227-1248, 1999). 26 The conventional hypothesis of hydroxyl radical DNA damage and 27 repair and excretion of the hydroxylated adduct 80H2'dG is that a hydroxyl 28 radical reacts with the DNA causing hydroxylation of the deoxyguanosine at 29 the 8 position. The damaged segment is then either excised by glycolysis as the δOhgua or by endonuclease excision as the 80H2'dG5'monophosphate. The monophosphate is then clephosphorylated and the 80H2'dG is rapidly excreted from the cell. The 80H2'dG excreted to the extracellular matrix is then cleared rapidly from the body primarily via the kidnev and excretion in the urine. δOhgua can also be produced as a result of attack on RNA and glycolysis. Studies performed with the technologies described above have confirmed certain basic elements of this hypothesis as follows: 1. Dialysis studies of 80H2'dG in extracellular matrix with probes placed in brain and muscle of rat and mouse to measure the rate of production and excretion compared with the free levels inside the cellular material confirm that excretion from the cells is rapid. Similarly, comparison of CSF, Plasma and urinary levels of ca 1:10:2000 in ca 100 ALS and control subjects confirm that the rate of clearance from the body is high. Studies of saliva or sweat vs. urine levels and studies showing highly elevated levels in plasma kidney dialysis patients confirm that urinary excretion is the primary mode of removal. 2. Studies of urinary levels of 80H2'dG within individuals over diurnal weekly, monthly and yearly intervals indicate that the rate of DNA damage and repair is highly constant and characteristic of an individual. Similarly, studies of siblings and parents which show a significantly closer agreement of sibling values indicate that the rate of DNA damage is strongly determined by genetic factors. Other studies, however, have indicated some basic difficulties with the simplistic model of damage and repair which have relevance to the use of DNA damage markers as diagnostic tools. 1. The simple model of increased production of hydroxyl radical leading to increased DNA damage is incomplete. 1 Comparison of total body rate of production of hydroxyl radical 2 estimated by salicylate spin trappings showed no correlation in normal 3 individuals, ALS patients and Freidrich's Ataxia FA patients of urine or 4 plasma levels of 80H2'dG. Nor was there any group elevation of total body 5 hydroxyl radical production in FA or ALS although the 80H2'dG levels were 6 increased in CSF plasma or urine by 25-30%. 7 Urine levels of SOH2'dG were significantly increased in individuals 8 exposed to arsenic or o-toluidine or aniline although these materials play no 9 direct role in the increase of hydroxyl radical production. 1.0 These studies suggest that conformational changes in DNA induced by 11 exogenous or indogenous adducts or changes in sub cellular structures in 1.2 proximity to DNA play a stronger role in increasing the rate of DNA damage 13 than overall hydroxyl radial production. Also supporting this concept are 14 studies 1 have performed showing no effect of simple antioxidants such as 15 Ascorbate or Tocopherol on the levels of 80H2'dG. 16 2. Relevant to the use of DNA damage rate measurements to 17 cancer diagnosis 1 have observed that in C. Elegans culture there is a burst of 18 80H2'dG production during the stage of rapid replication of the gonadal 19 cells. In similar experiments I observed that a toxin (3 nitro propionic acid, 20 3NP) increased the rate of DNA damage during replication. When the toxin 21 was removed after exposure the rate of damage was still maintained at a 22 higher level indicating that the initiation of a higher rate of damage creates a 23 biochemical state or feed back that persists beyond the time of the applied 24 insult. 25 3. It has also been observed in human controls, ALS patients and 26 FA patients and in C Elegans culture that the levels of 80H2'dG that remain 27 in the DNA (measured by extracting and hydrolyzing the DNA) are only 28 weeklv correlated with the rate of output of the 80H2'dG. This indicates that 29 both damage and repair are up regulated simultaneously and thus that 1 measures of the free levels of excised DNA damage product provide a much 2 more robust indicator of disorder related DNA damage processes. 3 4. In situations where there is a high rate of damage and repair the 4 conventional sequence of excision of the 80H2'dG phosphate, 5 dephosphorylation of the 80H2'dG and excretion of the 80H2'dG does not 6 hold, in rapid cell replication in C. Elegans, in 3NP insulted C. Elegans and in 7 Cervix cancer cells (as described below) the 80H2'dG phosphates are directly 8 excreted. 9 5. Sampling specific to the site of insult is of considerable 1.0 importance. In studies of smoking related increases of urinary 80H2'dG 11 levels, 1 have found a statistically significant increase of only 11% in a cohort 12 of ca 200 smokers vs. ca 300 control non-smokers. However, the free levels of 13 80H2'dG in the extra-cellular matrix from pharyngeal swabs of smokers vs. 1.4 non-smokers are elevated by a factor of 3x-4x when normalized against the 15 cellular metabolite of tyrosine, 4-hydroxy phenyl lactic acid. 16 The synthesis of these studies and observations leading to the 17 approach to cancer diagnosis is as follows: 18 1. When a cell begins extensive abnormal replication the changes 1 in the conformation of the DNA during mitosis maJke it more susceptible to 20 free radial damage and both increase the levels of excised damage products 21 and change the nature of those products. 22 2. Sample sites which are semi-isolated in situ from physiological 23 transport and excretion, reflecting the extracellular matrix around the affected 24 cells will show highly increased levels of the repair products relative to the 25 damage products remaining. 26 3. Levels of the repair products can be normalized against other 27 cellular metabolites that are excreted to the extracellular matrix from 28 metabolic processes that are not materially affected by free radical damage. 29 1 Working Examples 2 Cervico vaginal lavage samples were centrifuged on acquisition to 3 separate the exfoliated cells and the supernatant containing the extracellular 4 matrix. PAP smear sw'abs were vortexed in a normal saline solution and 5 centrifuged to separate the exfoliated cells and extracellular matrix. 6 Analysis for 80H2'dG in supernatants was accomplished in 7 accordance with the teachings of PCT/ US98/ 22275 using electrode 8 preparation and sample concentration protocol described in Bogdanor et al, 9 supra. Analysis for 80H2'dG phosphates was accomplished by treating a sub 10 aliquot of the supernatants with alkaline phosphatase following the last stage 1.1 of the DNA hydrolysis protocol described in Bogdanor et al, and 12 determination of the 80H2'dG phosphate level by difference between the 13 alkaline phosphatase treated and the non-treated aliquot. Chlorotyrosine 1.4 measurements of subaliquots of the supernatant were made according to the 15 teachings in PCT/ US98/ 22275 following the protocols in Bogdanor et al. 16 The process for determining appropriate normalizers and markers of 17 sample integrity was to prepare and analyze extracts of the supernate and 18 cells from cervico vaginal lavage and PAP smear samples, plasma red blood 19 cell and leucocvte samples, buccal cell samples and induced sputum samples 20 following the procedures in Kristal et al "Simultaneous Analysis of the 21 Majority of Low-Molecular Weight Redox-Active Compounds from 22 Mitochondria," Anal. Biochem. 263, 18-25(1998). Typically 600 peaks of redox 23 active compounds are isolated from such preparations. The various samples 24 were compared against themselves and against authentic reference standard 25 mixtures primarily to search for peaks or unknown compounds with the 26 following characteristics: 27 1. The peaks should be unique to cervico vaginal lavage or PAP 28 smear samples in order that it not be compromised by inclusion of other 29 cellular or biological material inclusion. 2. The peaks should be present in the supernate and not in the cellular extracts or at significantly higher relative concentration than the cellular extract in order to reflect a similar high rate of excretion from the cells a 80H2'dG. Secondarily, the patterns of cervico vaginal lavage an PAP smear samples were compared against urine and blood samples to determine the level for compounds that are highly elevated in blood, e.g. glutatione and urine, e.g. uric acid such that levels of these compounds indicate contamination and effects on 80H2'dG levels could be established. Of 16 peaks in the patterns meeting the criteria 1 and 2 Tyramine was identified. The other 15 peaks meeting the criteria are currently of unknown structure although they are also candidates for normalization. Levels of uric acid and glutathione in cellular material and supernate from cervico vaginal lavage and PAP smear samples established levels of ca 1000 ng/ l or uric acid and 50,000 ng/ml of glutathione below which no measurable impact on the 80H2'dG would be expected. A typical example of the comparison for known compounds among cell types is shown in Table 1. The carbon column switching instrumentation and the array instrumentation were combined by placing an 8 channel series sensor on the output of the first analytical column of the carbon column switching apparatus and a second 8 channel series sensor on the output of the second analytical column of the carbon column switching apparatus. This allowed the simultaneous determination of the uric acid glutathione and tyramine on the output of the first analytical column and the carbon column trapping, elimination of interferences and detection of 80H2'dG and Chlorotyrosine on the second analytical column. Figure 4 and 5 show typical responses for 80H2'dG and 06MG in PAP smear samples. The figures illustrate the detection of 80H2'dG in all samples and the limitation in detecting 06MG in some. 1 Figure 6 illustrates the CEAS patterns observed from cellular and 2 supernatant preparations. These were compared against each other and 3 against similar patterns of urine, plasma, whole blood and buccal cells to 4 determine normalizing compounds and indicators of sample quality. 5 The results of the analytical protocols and concepts applied to 51 6 cervico vaginal lavage samples from 51 patients with various diagnoses and 7 two normal PAP smear samples are shown in Table 1. 8 Table II presents the data on 80H2'dG, 06M.G vs. an abbreviated 9 diagnostic categorization ranked by tyramine divisor and sample weight or 10 weight estimated from protein. CVL and PAP smear samples are ranked 11 separately. Initial studies of vaginal vs. cervical swabs indicated higher levels 12 of tyramine in the former, it is thus likely that tyramine is not an optimum 13 normalizer since there are several other peaks that meet the criteria but have 14 not been chemically identified. Table III presents preliminary data on 15 relationships among free and DNA levels of SOH2'dG, in the cervix and urine 16 and plasma. There are some limitations on the data quality affecting 17 interpretation. Precision on small samples (less than 2 mg) is only +/-220- 1.8 30%. Storage histories are not completely documented and there are 19 uncertainties associated with any study of a new matrix. However, some 20 observations are indicated. 21 0\ © CΛ P H U a- σi η ^ O CM -* CM LO CD O 1- * C CD D CO σ L E o ri ro ffi CM --J- N CO N N ^f CM -5f O CO N N O n CB O ^ O O W CD oCO LNO cCnO ffl— c-o~ c~B- c—o a—i n— CM CD O CM LO CD -. CD O co o o o o o -5J" O o o o o o O CD O O CM CD O r-- - σ o LO -5}- CM m O O O CΩ N n N ra co N O H U α. a O CM CD LO CD 't ^ CO S N o LO CM CM CO 00 CM CO - CD h- N- CD CO CM CO - LO CO 00 CD ~ co 00 CD OO CO O -5t *0 o o O c\ en TABLE II CASE CODC 8C )H 1000/tyr DIAG COt )E 80H pg/gm 80H/C CASE CODE 8OH * 1000/tyr DIAG CODE 80H 'gm 80H/0 bMG CVt- SAMPLES cal by protten PAP SMEAR SAMPLES ESA006 1765222 C 108934 012 GON1R1 D92M 368 72 ESA041 519899 C 57132 COM2 103 N 442 112 ESA0447/21 382708 G 38897 CON3 083 M 293 141 ESA0447/16 345249 C 42132 024 CON4R1 072 M 528 NA ESA051 244130 G3 44150 CON1R5 CSA037 188184 G3 31988 endo brush 106 N 445 66 ESA011 160000 G NA exo brush 094 N 502 NA ESA048 137363 ADR 12012 Vaginal padl 012 N 28 NA ESA033R3 94082 ADR 18821 133 CON5R1 244 M 306 111 ESA025CVL 83573 AR 28812 CON4R3 098 M 122 43 ESA033R1 56489 AR 15166 CON5R3 187 N 354 75 ESA034 51359 ADR 12997 092 ESA030 51355 AR 19281 W001 219 AR 125 125 ESA043 51066 AR 12113 077 W002 41 AR 507 073 ESA038 50268 AR 23881 003 5826 Hepatitis 3855 057 ESA040 21530 AR NA W004 829 A R 200 056 ESA050 19787 AR 10667 192 W005 219 M 75 158 esa032s 12111 ADR 12188 006 43 MR 500 084 esa029s 7425 AR 2188 W007 21 N 90 071 ESA035 3850 ADR 1722 008 2749 N HPV 361 055 ESA018CVL 3574 AR 3221 W009 11304 ?AHPV 1300 045 ESA022CVL 2773 AR 3324 101 W010 09 "?A 75 168 ESA004 2253 AR NA W011 16 NR 75 12 ESA019CVL 2205 ADR 1922 W012 18 N 86 148 ESA0Q3 2053 AR 1334 013 11 N 75 12 ESA023CVL 2049 AR 1987 W014 18 NR 145 18 ESA001 1931 ADR 1332 W015 19 M 199 44 ESA039 1553 AR 1435 016 26 NR 301 43 ESA005 733 A 397 017 28 AR 190 13 ESA036 379 A 433 W018 312 A 412 19 esa027CVL 291 A 198 019 14 N 138 73 ESA047 156 M 163 GT10 W020 187 A 115 44 ESA012 148 N 289 W021 412 NR 543 17 ESA049 133 N 143 022 17 A 214 GT10 ESA020CVL 071 A 206 023 569 N HPV 3224 041 esa031s 071 N 134 024 21 AR 341 3 ESA046 064 N 289 W025 081 N 104 NA ESA021CVL 061 A 189 W026 23 NR 1 2 57 ESA0 2 057 N 215 027 28 AR 107 44 ESA045 045 N 127 GT10 028 16 N 115 81 ESΛ026GVL 036 N 131 ESA024GVL 018 N 156 N normal PAP A ASCIIS C cancer C3 CIN3 D dysplasla R vanos risk factors HPV PGR+ Viral te NA not analysed Interference o H U o o o o o o o o α. < -!— CO CD CM CO E v- CM < _l 1 ? ^ n_ Q - n o zs zs zs r^ ^ LU ϋ o r-~ o ^i- f~- o r-~ o o o o o CM oo co 00 ^J- ^r ^t- ^f r ^ ~- φ o o o o o o σ o o o o o o O o O o o o o o o o o o o o o o o c co CD CO O CO CD Q. co to co to to to to to to to to to to to to to to co t co co to to t o X) φ φ φ φ ω φ Φ φ φ φ Φ Φ φ Φ φ φ φ φ Φ Φ Φ φ φ φ Φ φ φ φ φ O c-x 1 RESULTS 2 Free levels of 80H2'dG in pg/ml were " 1.61 (normal case), 2.42 3 (precursor cell case) " 1 ,8-17.4 (dysplasia cases n=3) and 635.5 (cervical cancer 4 case). The values corrected for dilution by various measures of total protein, 5 amino acids or cell count, indicate initial concentrations in the extracellular 6 cervical environment of ca 80-110,000 pg/ml or -1000 times the normal 7 plasma levels of 10 pg/ml. This supports the hypothesis that the cervix is in 8 a biochemically isolated area. Ratios of 80H2'dG/2'dG in the DNA of 9 exfoliated cells were only elevated by factors of 2.1 and 4.8 in the Dysplasia 10 and cancer cases respectively vs. the normal. This also supports the 11 hypothesis that the effect of increase in both D A damage and repair is 12 magnified in the extracellular matrix in the cervix environment. 13 It is also consistent with the intuitively less probable hypothesis that ' 14 the DNA damage and repair is proceeding at a 20-100 fold higher rate in the 15 cervix. A weak correlation (r=0.431), driven by high values in the cancer 16 patients between urinary and cervical levels, is also consistent. In the cases 17 with repeat cervical samples, the values were consistent within an individual. 18 Urinary 80H2'dG values are highly individually specific and the same may 19 hold for the cervix. 20 The absolute levels of 80H2'dG based on estimates of the amount of 21 extracellular matrix from protein values in cervico vaginal lavage samples 22 and actual weights of PAP smear samples are on the order of 200-800 pg/ml 23 or ca 20-80 times the levels of 10 pg/ ml observed in plasma (2). This supports 24 the hypothesis and necessary diagnostic requirement that the cervix is a semi- 25 isolated in-situ area with respect to transport and excretion of DNA damage 26 products. 27 The very slight not statistically significant increase in DNA damage 28 products in the DNA itself supports the hypothesis that both damage and 29 repair are up regulated and that the effect is magnified in the extracellular 3U matrix. 1 While uncorrected 80H2'dG concentrations are statistically higher in 2 the cancer patients and patients at risk than in controls the use of Tyramine as 3 a normalize)" reflecting sample dilution and acquisition factors of the 4 extracellular matrix is effective in compressing the scatter of the data. 5 Tyramine normalized levels of 80H2'dG in all control samples and in 6 two cases of findings of Abnormal Squamous Cells of Uncertain Significance 7 (ASCUS) are all below the level of 1.6 pg 80H2'dG/ng Tyramine. All subjects 8 with identified cervix cancer and two with a high degree of suspicion of 9 cancer are about 16000 pg 80H2'dG/ng Tyramine. Patients with 10 intermediate possibly precancerous problems and risk factors have 1.1 80H2'dG/Tyramine ratios that are intermediate between control and cancer 12 and may predict an enhanced degree of risk of an early cancer that will 13 manifest subsequently. 14 The presence of measurable 80H2'dG phosphate as a significant 15 portion of the total 80H2'dG occurs in all the cancer cases and in three of the 16 cases with significant risk factors and initial per cancerous indicators. 17 Chlorotyrosine is found in seven cases and may in the case of ESA051 18 indicate a significant level of infection as well as or instead of an early cancer 1.9 lesion. 20 Thus, the invention and concept provides an index of 21 80H2'dG/Tyramine that separates cervical cancer subjects from controls by a 22 minimum factor of 1000 and gives intermediate values for various degrees of 23 risk and findings of abnormal or precancerous cells or lesions. A unique 24 marker of excretion of a portion of 80H2'dG as the phosphate is found in all 25 cancer subjects and may provide the first indicator of the culmination of risk 26 and insult factors in an early cancer in the individuals with high 27 80H2'dG/Tyramine ratios. The ability to commeasure markers of 28 inflammation and infection provides additional diagnostic discrimination 29 between risk factors and actual development of a cancerous lesion. Several possible candidates for dilution normalizing compounds also 1 were identified from application of a protocol for analysis of the majority of 3 oxidizable compounds in the cervical lavage supernate. Tyramine (TYRA) 4 notablv appears to be an attractive normalizer: — it is a uniquely elevated 5 product of cervical cellular metabolism relative to other cellular material 6 (Buccal cells, lymphocytes, alveolar and pharyngeal lavage, brain and muscle 7 dialysates); it is excreted rapidly to the extracellular matrix; and it is co- 8 determinable with 80H2'dG with the technology employed. For the six test 9 cases, the mole ratios of 8OH2'dGxl000/TYRA were: 1.48 (normal case), 7.34 10 (precursor cell case), 19.3-22.5 (Dysplasia cases n=3) and 17956 (Cervical 11 cancer case). 12 Thus, there appears to be a correlative decrease in 80H2'dG levels with 13 increased coQIO levels in plasma, or in the local in situ cervical area. 1.4. Accordingly, the analytical strategy of measuring both free and DNA levels of 5 80H2'dG in conjunction with the coQIO also provides a basis for 1.6 discriminating between changes in the rate of oxidative damage and changes 1 in the rate of repair associated with the coQl 0 levels. 18 The invention is susceptible to modification. For example, analysis of 19 stool samples for the presence and level of 80H2'dG and 80H2'dG 20 phosphates (which typically do not occur above about O.lpg/gm in normal 21 feces) both as timed or total output and normalized against levels of the 22 tyrosine metabolite gentisic acid may be employed as a diagnostic of colon or 23 lower bowel cancer; analysis of saliva for elevated levels of 80H2'dG may be 24 employed to provide an early test for esophageal or throat cancer; analysis of 25 urine or semen for elevated levels of 80H2'dG may be employed to provide 26 an early test for bladder or testicular cancer; pharvngeal or nasal swab, 27 alveolar or bronchial lavage samples for analysis of 80H2'dG normalized 28 against levels of 4-Hydroxy Phenyl lactic acid may be employed as a 29 diagnostic of pharyngeal, nasal, bronchial or lung cancer respectively; 1 analysis of foliated urithelial cells in timed culture for 80H2'dG levels 2 normalized against cell number or weight may be employed for diagnosis of 3 bladder or prostate cancer; analysis of menstrual blood for 80H2'dG leads 4 may be employed for early detection of ovarian cancer; analysis of phlegm for 5 elevated levels of 80H2'dG may be employed to provide an early test for lung 6 cancer; and analysis of throat swabs may be employed to provide an early test 7 for throat or esophageal cancer. 8 While not wishing to be bound by theory, it is believed that 80H2'dG 9 free level measurements represent the combined effect of the rate of DNA 10 damage and repair caused by disease conditions or environmental insults in a 11 living organism. Essentially, it is believed that the whole body rate of 12 production of 80H2'dG is: 13 (a) constant in an individual over time in the absence of 14 disease or environmental insult; 15 (b) genetically determined; 16 (c) not related to whole body rate of Hydroxyl radical 17 production; 18 (d) increased by environmental insult from putative DNA " 1.9 adducts (e.g. pyrenes, Toluidme Arsenic, etc.); 20 (e) increased in several neurodegenerative diseases; 21 (f) assessed equally well by spot and 24 hour urines; 22 (g) not affected by antioxidants tocopherol and ascorbate; 23 and 24 (h) not affected by diet and converted (via HCl and 25 glycolase) to 80H2'dGua in the stomach. 26 The clearance rate from cells and the body as a whole is believed to be 27 very rapid. Normally clearance is via urine but also may be by saliva and 28 sweat. If rates are accounted for there are compartmental correlations among 1 plasma and urine and saliva and DNA damage levels in leucocytes. 2 Typically, ca. 30% of the whole body 80H2'dG output is from the brain , 3 Compartmental correlations can be used to determine specific organ 4 involvement. For example, in C. Elegans culture there are bursts of 5 production during rapid mitosis. Isolated Mitochondrial preparations also 6 produce 80H2'dG in respiration. The relationships among different adducts 7 are different in rapid mitosis, stable cell number cultures and mitochondrial 8 cultures. Levels in DNA are only weakly correlated with rate of production. 9 Physiologically or transport isolated reservoirs concentrate the " 10 products and magnify the effects of DNA damage and repair, e.g. although 1 11 have measured only an 11% increase in urine levels of smokers, 1 have 12 measured a 400% increase in pharangeal swab samples. 1.3 Thus, it is believed that rates of DNA damage are primarily affected 1.4 by: (a) factors causing changes in the conformation of the DNA (mitosis, 15 binding of endogenous and exogenous adducts, transcription); and (b) 16 increases in free radical production in subcellular structures in close 17 dimensional proximity to the DNA (lipid bilayer, nuclear cytosol). The 1.8 damage and excision product profiles differ for mitochondrial and nuclear 19 DNA and by mechanism of damage. These observations are for cervical 20 cancer, but they are believed equally generalized to lung, lower bowel/colon, 21 prostate, bladder cancer, etc. as follows: 22 1. The cervix and the extracellular matrix of the cervix is an in situ 23 semi-isolated physiological area with respect to transport of excreted cellular 24 metabolites. 25 2. The product 8θH2'dC of the combined process of DNA damage 26 and repair is concentrated in the extracellular matrix of the cervix and 27 magnify and reflect the effect of these processes more than the levels of the 28 damage products remaining in the DNA. 3. Correlative or normalizing markers for control of sample dilution and acquisition effects can be selected from metabolites that are (a) not affected by free radical processes, (b) excreted from the cells at a rapid rate, or (c) unique or predominant to the metabolism of cervical cells. 4. The rate of production of DNA damage/repair products will be increased when the cells in the cervix are (a) undergoing rapid division, (b) exposed locally to increased free radical insult as from infection or inflammation, (c) exposed to increased levels of DNA conformation modifying adducts from endogenous processes (metabolic shifts) or exogenous sources (bacterial, or viral infections and/ or environmental toxins). 5. The combination of the factors increasing the rate of DNA damage will constitute a risk factor for cancer which will be reflected in higher levels of DNA damage and repair product 80H2'dG in the extracellular matrix. 6. The magnitude of the different mechanisms of DNA damage will differ and rapid cell division will predominate. Thus, rates of DNA damage in cancer cases and extracellular levels of 80H2'dG will be significantly higher than in cases of ASCUS or with dysplasia or other risk factors. 7. The relative levels of DNA damage and repair products will differ for different mechanisms. Cancer cells will excrete a significant portion of the endonuclease excised 80H2'dG as the phosphate or monophosphate, and excise a higher proportion of the damaged base by glycolase excision resulting in elevated levels of 80H2'dGua in the extracellular matrix. Cancer cells will also preferentially excrete elevated levels of 5-Oxocytidine and reduced levels of 8-nitro guanine. 8, The absolute and relative levels of 80H2'dG, 80H2'dC Phosphates, 80H2'dGua, 8 nitroguanine and 5 Oxocvtidine will constitute a profile indicating the presence of cancer independent of the cvtological results of the PAP smear and levels of risk factors. 9. The absolute and relative levels of DNA damage products will provide an early indication of cells that are in a precancerous state. 10. Co-determined markers of other free radical damage products will serve to further differentiate the nature of and extent of damage from other risk factors to the rate of DNA damage. Notably chlorotyrosine will serve as an indicator of the effect of inflammation or infection and nitrotyrosine as a normalizer for peroxynitrite DNA damage processes. It is thus seen that: 1. The levels of 80H2'dG in cervical vaginal lavage normalized by protein or in PAP smear samples from controls normalized by weight are ca 250-500 pg/ ml of extracellular matrix or ca 25-50 times plasma. This is in contrast to the free extracellular levels in muscle, brain, liver, etc. which are on the order of ca l-3pg/ l. Therefore, the cervix is seen as semi-isolated with respect to metabolite transport. In cancer cases where the levels of 80H2'dG in the extracellular matrix are ca 100 times higher than in controls the levels in DNA from the exfoliated cells are only increased by 35% and the difference is not statistically significant. So the concentration of the products in the se i- isolated area magnifies the effect of the DNA damage rate. 2. Using pattern generating techniques to compare cell extracts and extracellular matrix from CVL, PAP smear, buccal cell and alveolar lavage samples and also plasma, red blood cells and urine, the following has been observed: In CVL and PAP smear samples 23 candidate peaks were over lϋx more concentrated in the extracellular matrix, 3 where highly elevated or unique in the CVL/ PAP smear samples over all other types. Tyramine was identified as one of these which should be minimally affected by free radical processes and was selected as a sample acquisition normalizer. Note on an 1 operational basis these studies also served to provide acceptable levels of 2 sample quality indicators, e.g. uric acid for urine contamination and 3 glutathione for blood inclusion. 4 3. The ratio of 80H2'dG/ tyramine seems to indicate that the rate 5 of damage is higher with cancer and with various risk factors which may 6 include HPV infection, other STD's, multiple partners, hisuitism, endocrine 7 abnormalities, and various equivocal findings from colposcopy. 8 4. There appears to be a gradation in the increase in rate of DNA 9 damage that is generally in the same direction as increase in risk factors. 0 5. Even if any of the assumptions are wrong, the rates of local 11 DNA damage in the cervix in the cancer cohort is much higher than in the 12 controls or at risk cohort. Thus, a viable cancer screening test subsists. 13 6. Some 80H2'dG phosphate is always seen in cancer. Thus, when 14 it is seen in subjects with high rates of DNA damage and other risk factors it is 1.5 likely that they actually do have cancer, but it just hasn't advanced to a point 16 where it can be conventionally detected yet. The 80H2'dGua/80H2'dG ratio 1.7 was 20 fold higher in two cancer patients than in 8 controls and an algorithm 18 based on ratio and absolute level separates the categories by a factor of 20,000. 1.9 The invention is susceptible to modification. For example, the above 20 technique may be employed to assay free levels of the primary oxidative 21 DNA excision product 8-hydroxy-2'-deoxyguanosine (80H2'dG) and sample 22 normalizing compounds in pharyngeal swabs, induced sputum, bronchial 23 and alveolar lavage using carbon column switching liquid chromatography 24 electrochemical detection (LCEC) as above described. Preliminary work 25 shows three fold elevations of 80H2'dG in sputum and pharyngeal swabs in 26 smokers. The absolute levels of 80F12'dG are 10-30 times greater than in 27 plasma which supports an initial hypothesis that the respiratory tract is a 28 semi-isolated physiological transport limited area in which the process of 29 DNA damage and repair will be magnified. In the cervix, a similarly semi- ' 1 isolated physiological area, cancer patients shown 2000-10000 fold elevations 2 of 80H2'dG over controls. Thus, there is provided a diagnostic or risk 3 assessment biochemical test for respiratory lesions. 4 As before, and while not wishing to be bound by theory, the overall 5 hypotheses is that: 6 1. The respiratory tract is a semi-isolated physiologically transport 7 limited area in which the effects of DNA lesion repair will be magnified. 8 2. Increased DNA damage will be coupled with up regulated 9 repair and thus the free levels of repair products in the extracellular matrix of U the respiratory tract and thus will be more indicative of risk or presence of 11 disease than the levels in the DNA itself. 12 3. The levels and nature of DNA and RS damage products will 13 differ among processes of DNA ligand formation, increased reactive species 14 product, inflammation/ infection and rapid cell mitosis, necrosis and 15 apoptosis and thus provide a route to diagnosis or risk assessment. 1.6 The assay of 80H2'dG and potential sample normalizers in pharyngeal 1.7 swabs, induced sputum and bronchial alveolar lavage samples, urine, plasma 18 and leukocytes from cohorts of controls, individuals with various risk factors 1.9 and individuals with respiratory tract lesions using existing technologies 20 permits the determination of the correlations and compartmental 21 relationships among the different sample types and the different diagnostic 22 categories for 80H2'dG and sample normalizers. This in turn permits 23 evaluation of correlative and process relevant reactive species markers: 8- 24 Hvdroxyguanine, 8-Hydroxyguanosine (glycolase excision and RNA damage 25 markers); 7-Methyl guanine (DNA methylation marker); 3-Nitrotyrosine and 26 8-Nitroguanine (peripheral and DNA reactive nitrogen markers) and 3- 27 Chlorotyrosine (infection or inflammation marker). 28 The invention also provides strong evidence for concurrent 29 methylation increases in N methyl and NNdimethyl Serotonin (NM5HT NNM5HT) and 7Nmethyl Guanine (7MG) in plasma and CSF and reduction in the oxidative DNA damage marker 8-Hydroxy 2'Deoxyguanosine (80H2'dG) in stroke and ischemia in humans. More particularly employing the analysis techniques of the present invention shows a reduction in CNS production of the oxidative DNA damage product 8-Hydroxy-2'- deoxyguanosine (80H2'dG) and an increase in the production of methylated compounds in a cohort of stroke patients and a similar reduction of 80H2'dG levels in animal stroke models. Thus, elucidation of the biochemical mechanisms of methylation and oxidative free radical damage to DNA and other cellular structures in stroke and related disorders, and the determination of the relationships of the biochemistry to stroke management, provides a rapid single assay technology for methylated, reactive oxygen and nitrogen species (ROS, RNS) markers in clinically accessible samples and samples relevant to mechanistic studies in animal models. This provides for clinical management of and the evaluation of pharmacological intervention in stroke. Preliminary work with purine specific carbon column switching techniques as above described also demonstrates elevations of the DNA hydroxy radical damage marker 8-hydroxy-2'-deoxyguanosine in a number of neurodegenerative diseases (NDD). Progressive increases with disease have been shown in, e.g. amyotrophic laterial sclerosis. That is to say, preliminary work with carbon column switching LCEC technology in accordance with the present invention has shown that the ROS DNA damage marker 8-hydroxy- 2'deoχyguanosine (80H2'dG) is elevated in Parkinson's Disease (PD) (urine, plasma, and CSF), Alzheimer's Disease (AD) (plasma and urine, Hunhngton's Disease (HD) (urine), Freidrich's Ataxia (FA) (urine plasma) and that it is elevated and progressive with time in Amyotrophic Lateral Sclerosis (ALS) (urine plasma and CSF) but not in mvopathies. Secondary evidence from the patterns of chromatograms determining 80H2'dG indicate differences in 1 unidentified purine adducts in urine plasma and CSF among the 2 neurodegenerative disorder (NDD) categories. Again, while not wishing to 3 be bound by theory, the overall hypothesis is as follows: 4 1. DNA damage products resulting from processes of 5 methylation/ ROS/ RNS/ RCLS are different among controls and NDD. 6 2. Ligand of endogenous/exogenous compounds with DNA play a 7 role in increased DNA damage. 8 3. Excision and repair processes differ among controls and NDD. 9 4. The sites of attack of RS on DNA differ among controls and 10 NDD. 1.1 As mentioned supra, other DNA and RNA damage markers and free 12 radical markers may be assayed as indicators for the presence of or risk of 13 various health disorders. 1.4 Table IV below lists preliminary conditions developed for DNA 15 damage markers and free radical markers established for the purpose of 16 establishing approximate levels of the analytes of interest. Urine, plasma and 17 cervical extracellular matrix values are presented for pooled control samples. 18 The basic sensitivity of all procedures is from 10-50 pg/ml (500-2500 fg on 19 column). 20 TABLE IV MEOH - methanol An-acetonitrile; B1 - lithium acetate 0.1 M pH 6; B2 - lithium phosphate 0.1 M pH 3; B3 - pentone sulfonic acid 0.1 M pH 4; Column Types: 1- Tosobaas C18 ODS 80 TM; 2 - YMC C8 Y02H1 carbon column; A- 4 6 mm d x 4.6 mm; B - 4.6 mm d x 8 mm; C - 4.6 mm d x 13 mm; ADN - adenosine; DD - dodecane; NBA - nitrobenzoic acid; ND - not detected It is thus seen that the present invention provides an objective reproducible test for cervical cancer and pre-cancer screening, as well as for early detection of various other cancers and other health conditions including heart disease and various degenerative diseases.

Claims: CLAIMS 1. A method for detecting a health condition of a living organism comprising electrochemically analyzing samples from selected areas of the body of said living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage. 2. A method according to claim 1, wherein said nucleotide excision products are selected from the group consisting of 80H2'dG, 06MG, 2'dG, 7 G, 8NG, 80HG, 80H2'dA, 80HA, 5)H2'dcy, 50HU, 3NT and 3CIT. 3. A method according to claim 1, wherein the samples comprise stool samples, and the health condition comprises colon cancer. 4. A method according to claim 1, wherein the samples comprise saliva, and the health condition comprises esophageal or throat cancer. 5. A method according to claim 1, wherein the samples comprise urine, and the health condition comprises bladder or testicular cancer. 6. A method according to claim 1, wherein the samples comprise phlegm, and the health condition comprises lung cancer. 7. A method according to claim 1, wherein the samples comprise cervico vaginal lavage , an endocervical swab or brush sample, and the health condition comprises cervical cancer. 8. A method according to claim 7, and including the step of analyzing for Tyramine, and comparing the mole ratios of SOH2'dG to Tyramine. 9. A method according to claim 1, wherein the samples comprise buccal or pharyngeal swab samples and the health condition comprises pharyngeal or nasal cancer. 1.0. A method according to claim 1, wherein the sample comprises exfoliated urithelial cells and the health condition comprises bladder, testicular or prostate cancer. 11. A method according to claim 1, wherein the sample comprises ? induced sputum, or alveolar or bronchial lavage, and the health condition 3 comprises lung or bronchial cancer. 4 12. A method according to claim 1, wherein the sample comprises a 5 standard PAP smear endocervical swab or brush sample and the health 6 condition comprises cervical cancer. 7 13. A method for determining normalizing compounds for sample 8 volume and acquisition variables for the measurement of nucleotide excision 9 products resulting from DNA or RNA damage in a living organism 10 comprising the steps of: determining the levels of potential normalizing 11 compounds in cellular and extracellular material from a sample site; selecting 12 compounds that are unique to or enhanced by metabolic processes of that 13 sample site, selecting from these compounds that are significantly higher in 14 the extracellular than in the cellular material from that sample site. 15 14. A method according to claim 13, for detecting esophageal or 16 throat cancer, wherein the extracellular material comprises saliva, and 1.7 wherein the normalizing compound is 4 hydroxy phenyl lactic acid. 18 15. A method according to claim 13, for detecting lung or bronchial 19 cancer, wherein the extracellular material comprises sputum, or alveolar or 20 bronchial lavage, and wherein the normalizing compound is 4-hydroxy 21 phenyl lactic acid. 22 16. A method according to claim 13, for detecting cervical cancer 23 wherein the extracellular material comprises a cervico vaginal lavage, an 24 endocervical swab or brush sample, and wherein the normalizing compound 25 is tyramine and the diagnostic is the ratio of 80H2'dG to Tyramine. 26 17. A method according to claim 13, wheein said nucleotide 27 excision products are selected from the group consisting of 80H2'dG, 06MG, 28 2'dC, 7MC, 8NG, 80HG, 80H2'dA, SOHA, 5)H2'dcy, 50HU, 3NT and 3C1T. 18. A method of codetermining chlorotyrosine as a marker of infection to improve the diagnostic specificity of the 80H ' l 'dG and 80H2'dG phosphate levels.

Inventors: MATSON WAYNE, MATSON, WAYNE
Applicants: ESA INC, MATSON WAYNE, ESA, INC., MATSON, WAYNE
Application year: 2001
Main classification: A61B
IPC codes: C07H21, C12Q1, G01N30, G01N33